Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DBV Technologies's Enterprise Value is $-5.74 Mil.
DBV Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-76.54 Mil. Therefore, DBV Technologies's EV-to-EBIT ratio for today is 0.07.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, DBV Technologies's Enterprise Value is $-5.74 Mil.
DBV Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-67.37 Mil. Therefore, DBV Technologies's EV-to-EBITDA ratio for today is 0.09.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, DBV Technologies's Enterprise Value is $-5.74 Mil.
DBV Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, DBV Technologies's EV-to-Revenue ratio for today is .
DBV Technologies Enterprise Value Historical Data
The historical data trend for DBV Technologies's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DBV Technologies's Enterprise Value
For the Biotechnology subindustry, DBV Technologies's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Enterprise Value distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Enterprise Value falls into.
DBV Technologies Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
DBV Technologies's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies (NAS:DBVT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
DBV Technologies's current Enterprise Value is $-5.74 Mil.
DBV Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.54 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
DBV Technologies's current Enterprise Value is $-5.74 Mil.
DBV Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.37 Mil.
DBV Technologies's current Enterprise Value is $-5.74 Mil.
DBV Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies Enterprise Value Related Terms
Thank you for viewing the detailed overview of DBV Technologies's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
DBV Technologies (DBV Technologies) Business Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DBVT has been successfully added to your 